Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05907122 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 256
- Enrollment target
NCT05907122 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 256 participants.
The verdict
NCT05907122, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 256 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the pharmacokinetic (PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma.
Interventions
- DRUG ABP 206
- DRUG FDA-licensed Nivolumab
- DRUG EU-authorized Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2023-07-26 |
| Est. Completion | 2025-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05907122
The ClinicalTrials.gov registry entry for NCT05907122 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ABP 206 is the first listed.
NCT05907122 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05907122 about?
NCT05907122 is a clinical study titled "A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma". The purpose of this study is to investigate the pharmacokinetic (PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma.
What is the current status of trial NCT05907122?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 256 participants. The study started on 2023-07-26. Estimated completion is 2025-10-31.
What interventions are being tested in trial NCT05907122?
The interventions under investigation include: ABP 206 (DRUG), FDA-licensed Nivolumab (DRUG), EU-authorized Nivolumab (DRUG).
Who is sponsoring clinical trial NCT05907122?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.